With its 120-patient target reached, encouraging early durability data and a November investor calendar, Eupraxia Pharmaceuticals is building a more substantial case for long-acting drug delivery.
Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is approaching the kind of stretch that can move a…